Hydrogen therapy shows promise for cellular health and longevity at Tokyo health summit

Innovative gas inhalation technology demonstrated potential to reduce oxidative stress and boost immune function through atomic hydrogen delivery

At the Hololife Summit in Tokyo, Japanese manufacturer Masahisa Miwa presented compelling research on a novel approach to cellular health: the therapeutic use of atomic hydrogen gas. Speaking to health professionals and researchers gathered in Japan's capital, Miwa outlined how his company's patented dry cell technology produces what he calls HHO gas—a reactive combination of atomic hydrogen and oxygen that differs fundamentally from standard molecular hydrogen.

"At the origin of all matter lie atoms, the building blocks of life," Miwa told attendees. "Among them, hydrogen is the most abundant and the simplest, and when it combines with oxygen, the rejuvenation of life and healing begins."

The oxidative stress problem

Central to Miwa's presentation was the body's ongoing struggle with oxidative stress. Whilst oxygen remains essential for survival, reactive oxygen species—particularly the hydroxyl radical—can damage cellular components including lipids, DNA, and proteins. These molecules emerge as natural byproducts of metabolism, but when their levels exceed the body's antioxidant defences, the resulting oxidative stress contributes to conditions ranging from cardiovascular disease to neurodegeneration.

"Oxygen, essential for survival, can silently corrode life from within when left unchecked," Miwa explained, "but hydrogen's reactive nature becomes life-saving by neutralising the deadly hydroxyl radical."

Unlike molecular hydrogen, which remains relatively stable and inert, atomic hydrogen in HHO gas possesses unpaired electrons that make it highly reactive. According to Miwa, this reactivity proves critical when confronting hydroxyl radicals, as the atomic hydrogen donates its free electron to neutralise these dangerous molecules, converting them into harmless water.

Clinical evidence and applications

Miwa presented data from multiple clinical trials conducted in partnership with Japanese universities and medical institutions. Research conducted by Dr Kondo from Osaka University involved participants using the inhalation device for one hour daily over two months. Results showed improvements in cholesterol balance, with both LDL and HDL levels normalising, alongside benefits for diabetic patients including improved HbA1c levels and blood glucose control.

Additional trials examined effects on cancer markers, with Miwa citing dramatic reductions in tumour markers for ovarian and breast cancer patients using the therapy. Research with Dr Ochiya at Tokyo Medical University demonstrated reduced reactive oxygen species in cancer cells during in vitro studies.

The technology has found adoption beyond clinical settings. Approximately 25 per cent of customers are athletes, according to Miwa, with users including Japan's under-23 volleyball team, WBA boxing champions, and professional racing drivers. The devices have also been deployed in over 200 salons and clinics across Japan.

Mechanism of delivery

The therapy works through inhalation, with HHO gas entering the body via the lungs and eyes. "When HHO gas is inhaled, it travels through our vital gateways, enters the bloodstream, and reaches every cell," Miwa explained, "enabling hydrogen to rapidly act on oxidative stress and support cellular function."

Once in the bloodstream, the atomic hydrogen circulates through the body's estimated 97,000 kilometres of blood vessels, reaching cells throughout the system. At the cellular level, the hydrogen appears to support mitochondrial function—the organelles responsible for energy production.

"With an added supply of hydrogen, the mitochondria produce ATP more efficiently," Miwa noted, "resulting in greater vitality, faster recovery, and resilience at the cellular level."

Technical innovation and safety profile

What distinguishes Miwa's technology from other hydrogen therapies lies in the dry cell production method, which has secured international patents including in the UK. Unlike wet cell systems used by competitors, the dry cell technology produces what Miwa describes as substantially higher concentrations of atomic hydrogen—measuring between 650,000 and 660,000 parts per million according to Japanese Food Administration references.

Chromatography testing presented at the summit showed the devices producing higher levels of nanoparticles (0-200 nanometres) compared to competitor machines. The technology requires minimal power—roughly equivalent to a desktop computer or coffee machine—and the devices remain portable enough to fit in a standard suitcase.

Safety represents a key consideration. Miwa emphasised the therapy's lack of documented side effects, rapid cellular penetration, and selective action on inflammatory markers and oxidative stress. The devices require no replacement parts and the company handles maintenance directly.

Broader implications

The presentation highlighted diverse applications beyond disease treatment. Trials demonstrated improvements in skin moisture content and growth factors, with epidermal and insulin-like growth factors showing increases of four-fold and nine-fold respectively in PCR testing. Weight management benefits emerged as well, attributed to improved mitochondrial health and metabolism.

Immune function appeared to benefit significantly. Studies showed increased natural killer cell counts and lymphocytes, alongside reduced cytokine storm markers in vitro—findings with potential relevance to conditions involving immune dysregulation.

"Our patented dry cell technology produces atomic hydrogen gas that penetrates cells quickly, reducing inflammation and oxidative stress, boosting the immune system, and supporting efficient energy generation," Miwa summarised.

Questions remain

Whilst the clinical data presented appeared promising, the presentation raised questions typical of emerging therapeutic technologies. Long-term efficacy studies, larger randomised controlled trials, and peer-reviewed publication of results would strengthen the evidence base. The mechanisms by which atomic hydrogen exerts its effects, whilst plausible based on known chemistry, require further elucidation through rigorous scientific investigation.

The therapy's integration into mainstream medical practice also faces hurdles including regulatory approval processes across different jurisdictions, standardisation of treatment protocols, and comparative effectiveness research against established therapies.

Nevertheless, the technology represents an intriguing approach to addressing oxidative stress—a factor implicated in ageing and numerous chronic diseases. As research into hydrogen therapy continues to expand globally, innovations like Miwa's dry cell system contribute to a growing body of knowledge about potential therapeutic applications of this most fundamental element.

For attendees at the Tokyo summit, the presentation offered a glimpse into how ancient elements might be harnessed through modern technology to address contemporary health challenges, from cellular ageing to immune dysfunction to metabolic disease.

Frequently asked questions

What is HHO gas and how is it delivered?

Masahisa Miwa's patented dry cell technology produces HHO, a reactive combination of atomic hydrogen and oxygen. It is taken by inhalation, entering through the lungs and eyes, then circulating in the bloodstream so the hydrogen can act on oxidative stress and support cellular function.

What concentration does the dry cell produce?

Miwa said the dry cell method yields between 650,000 and 660,000 parts per million of atomic hydrogen according to Japanese Food Administration measurement, substantially higher than the wet cell systems used by competitors. The method holds international patents, including in the UK.

What did the clinical trials show?

In work with Dr Kondo at Osaka University, participants used the inhalation device for one hour daily over two months and showed normalising LDL and HDL levels alongside benefits for diabetic patients. Other trials reported improved skin moisture, with epidermal and insulin-like growth factors rising four-fold and nine-fold in PCR testing.

About the event

This recap is part of the HOLOLIFE Summit 2025 Tokyo series, recorded in Tokyo on 10 and 11 October 2025. Read the summary of the whole event or join the next edition, HOLOLIFE Summit 2026 Amsterdam, on 14 and 15 November 2026.